Prenetics Global Limited
PRE
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $432.5M
$25.44
▼ -0.74%
P/E
-13.53
Mkt Cap
$432.5M
52-Wk Range
$8.10–$27.24
52-Week Range
$8.10 - $27.24
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 170.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+27.2% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PRE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 18, 2026
Reported EPS of -$0.53 vs -$0.84 consensus (+36.9% surprise). Revenue of $46.5M vs $49.9M expected (-6.7%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+36.9%
Revenue trend · last 2Q
—
+163%
Q1 26
Q2 26
$36.0M
$46.5M
Margins · last 2Q
Gross
65.0%
Operating
-47.1%
Profit
-19.3%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: B. Riley · Aug 27, 2026
vs Industry
How PRE stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.